Neurocrine Biosciences Chief Medical Officer Files Initial Form 3 Statement of Beneficial Ownership

Executive Summary

On October 7, 2026, ROBERTS EIRY, Chief Medical Officer of NEUROCRINE BIOSCIENCES INC ($NBIX), submitted an initial statement of beneficial ownership on SEC Form 3 reflecting holdings as of September 28, 2026.

Holdings Breakdown

Non-Derivative Securities (Table I)

• Common Stock: 51,331 shares beneficially held directly (Footnote 1 indicates 50,146 shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, over which Dr. Roberts retains voting and investment power).

Derivative Securities (Table II)

Dr. Roberts holds numerous stock option grants and restricted stock units (RSUs):

• Stock Options (NQSO & ISO):
  • 17,147 options @ $102.90 expiring 2030-02-06
  • 48,199 options @ $117.63 expiring 2031-02-08
  • 60,005 options @ $79.02 expiring 2032-01-31
  • 965 ISOs & 51,567 NQSOs @ $103.52 expiring 2033-02-13
  • 747 ISOs & 21,782 NQSOs @ $133.84 expiring 2034-02-13
  • 27,770 options @ $136.69 expiring 2034-12-17
  • 853 ISOs & 42,408 NQSOs @ $117.18 expiring 2035-02-12
  • 10,087 options @ $124.12 expiring 2036-02-13
• Restricted Stock Units (RSUs):
  • 2,114 RSUs vesting February 13, 2027
  • 2,242 RSUs vesting through February 13, 2028
  • 2,743 RSUs vesting through February 13, 2028
  • 6,081 RSUs vesting through February 12, 2029
  • 2,949 RSUs vesting February 13, 2027

Market Significance

Form 3 filings report initial holdings when an insider becomes subject to Section 16 reporting requirements. Because this filing reflects baseline ownership and unexercised equity awards rather than open-market purchases or sales, the trading significance is categorized as Low.